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IVERMECTIN-ALBENDAZOLE COMBINATION THERAPY IN LYMPHATIC 
FILARIASIS OF THE UPPER LIMB: CASE REPORT
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The commonest manifestation of lymphatic filariasis is lymphoedema, which on progression leads on to 
elephantiasis. Even though lower limbs are commonly affected, upper limbs involvement is rarely reported in West 
Africa especially in females.  In the present report a 19 year old female (BMI 20.49 kg/m2) in the West-African sub-
region presented with swelling of the right upper limb of 4 weeks duration with associated pruritus and 
hyperpigmented lesions interspersed with hypopigmentation in the affected limb. There was a dramatic recession in 
the lymphoedema within 2 weeks following the administration of ivermectin and albendazole combination therapy. 
The adverse effect observed following the use of this combination was mild. This confirms the efficacy and safety of 
the above combination in the management of lymphatic filariasis.
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INTRODUCTION
Lymphatic filariasis is caused by the lymphatic-
dwelling nematodes; Wuchereria bancrofti, Brugia 
malayi and B timori that are transmitted to humans
by mosquitoes (Pani et al., 2005; Kaliwal et al.,
2010). It is a common tropical parasitic disease 
affecting an estimated 120 million people in the 
world (WHO 2010). About one-third of the affected 
population lives in India (Swaminathan et al., 2012).
Wuchereria bancrofti accounts for approximately 
90% of the disease burden while Brugia malayi
contributes the remaining 10% (WHO 1992).  Second 
to psychiatric illness, it is the leading cause of 
permanent and long-term disability (WHO 1995, 
Emilio 2008). Advances in medical science have 
helped not only in better understanding of the 
pathogenesis of this disease, but also in the diagnosis, 
management and in planning effective strategies for 
its global prevention. Newer understanding in the 
clinical manifestations has helped to improve the 
current trend in management (Ottesen and 
Ramachandran, 1995). 
In an endemic area, the largest group of affected 
individuals are healthy young adults and children 
who in-spite of being clinically asymptomatic,
harbour microfilaria in their peripheral blood (Anitha
and Shenoy, 2001).It is important to note that even at 
this stage of the disease, abnormalities of the 
lymphatic vessels like dilatation appears to be 
irreversible even after treatment (Freedman et al., 
1994).  Attacks of fever and chills due to acute 
adeno-lymhangitis are the commonest acute 
manifestations, which occur in the affected limbs or 
sometimes involve the genitalia. These episodes may 
be seen both in the early and late stages of the 
disease. The affected area is painful, tender, warm, 
red and swollen. The lymph nodes in the groin and 
axilla, are frequently inflamed. These acute adeno-
lymhangitis attacks recur many times a year in 
patients with filarial swelling, their incidence 
increasing with the degree of lymphoedema. 
Secondary infections due to bacteria like streptococci 
are responsible for these acute episodes (Suma et al.,
1997). In the affected limbs, lesions which favour 
entry of these infecting agents can be demonstrated, 
either in the form of fungal infection in the webs of 
the toes, minor injuries, eczema, insect bites or 
infections. 
These adeno-lymhangitis attacks are responsible for 
the persistence and progression of the swelling 
leading to elephantiasis not only of the limbs but also 
of the external genitalia and breasts (Shenoy et al., 
1999). Acute manifestations directly caused by adult 
worms are usually rare. They are seen when the adult 
worms are destroyed in the lymphatics either 
spontaneously or by drugs like diethylcarbamazine. 
Small tender nodules form at the location of dead 
adult worms either in the scrotum or along the 
lymphatics. Additionally, lymph nodes may become 
tender and inflamed, large lymphatics may stand out 
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as long tender cords underneath the skin, usually 
along the sides of chest or the upper arm and axilla 
associated with restriction of movement of affected 
limb. Though transient oedema may occur 
sometimes, these episodes are not associated with 
fever, toxemia or evidence of secondary bacterial 
infections. They generally subside without any 
treatment (Emilio, 2008).
The commonest chronic manifestation of lymphatic 
filariasis is lymphoedema, which on progression 
leads on to elephantiasis. Though lower limbs are 
commonly affected, upper limbs and male genitalia 
are also involved. In females rarely, the breast and 
the external genitalia may also become elephantoid 
(Dreyer et al., 1997; Emilio, 2008). In repeated 
adeno-lymhangitis, episodes responsible for the 
progression of lymphoedema continue to occur. This 
is due to the fact that the presence of moisture in the 
web spaces of the closely apposed swollen toes 
promotes fungal infections damaging the skin, which 
in turn favour infecting organisms. For this reason, 
the frequency of adeno-lymhangitis episodes is 
shown to increase in the rainy season, when people 
have to wade through water in the lanes (Shenoy et 
al., 1998). Elephantiasis resulting from B.
malayi infection typically affects the distal portions 
of the extremities. Unlike bancroftian filariasis, B. 
malay rarely affects genitalia and does not cause 
funiculitis, orchitis, epididymitis, hydrocele, or 
chyuria; conditions more readily observed with 
bancroftian infection (John and Petri, 2006).
CASE REPORT
Clinical Presentation: The case involves a 19 year 
old girl from the South West geo-political zone of 
Nigeria. Two years prior to presentation she was 
resident in a riverine community in Sabo, Edo State, 
before relocating to Ekpoma also in Edo State, 
Nigeria. While in Sabo, the patient went to the river-
side to swim once. Two years after, she presented 
with a 4 week history of swelling of the right upper 
limb with associated intense pruritus in the affected 
limb. The patient also noticed intense feeling of 
tightness in the affected limb aggravated by placing 
the limb in water. This was preceded by a sudden 
onset of intermittent febrile episode and headaches. 
On examination patient was found to have unilateral 
oedema of the right upper limb with evidence of hypo 
and hyper-pigmented skin lesions in the affected 
limb. However, there was no evidence of peripheral 
lymphadenopathy.
An initial assessment of lymphatic filariasis was 
made. Blood samples were collected for microscopy, 
hematological and biochemical investigations. Urine 
sample was also collected for analysis.
Laboratory Findings: Microscopy
 Giema Stain: Plasmodium falciparum
present. Parasite count = 380/µL, 
microfilaria not seen in blood film.
 Wet mount preparation of Serum:
Wuchereria bancrofti present (see plate 1 
and 2)
 Wet mount preparation of urine: 
Microfilaria absent.
 Full Blood Count: PCV =37%, 
Hb=12.3g/dl, WBC=6800/mm3. Differential 
count: Lymphocytes = 63%, Neutrophils =
36%, Monocytes = 1%, Eosinophils = 0%, 
Basophils = 0%
Urinalysis
 Appearance: Slightly turbid.  Colour: amber
 Blood, bilirubin, glucose, ketone and nitrite 
= negative
 Urobilinogen = 0.2, pH = 9.0, Specific 
gravity =1.005
Liver Function Test
 Total bilirubin = 0.4 (0.1-1.1) mg/dl; 
Conjugated Bilirubin = 0.2 (≤0.5) mg/dl
 AST =15 (≤12) I.U/L; ALT=11 I.U/L (≤12) 
I.U/L; Alkaline phosphate=57 (9-35) I.U/L
Electrolyte/Urea/Creatinine
 Potassium=3.6 (3.5-5.3) mmol/l; Sodium= 
139 (135-140) mmol/l
 Urea= 13 (10-55) mg/dl; Creatinine=0.7 
(0.7-1.4) mg/dl
DISCUSSION
This report revealed a rare case of lymphatic filariasis 
of the upper limb in Ekpoma, Edo State, Nigeria. 
Surprisingly, lymphadenopathy and eosinophilia 
were absent at presentation. Additionally, the 
electrolyte status and hematological findings were 
essentially normal. Worthy of note was the dramatic 
response observed following the administration of a 
single dose combination of ivermectin (0.2mg/kg) 
and albendazole (400mg). Two days (48 hours) after 
the use of these agents, the patient complained about 
a more intense pruritus which receeded after the 
administration of intramuscular promethazine. In the 
management of this condition the use of crepe 
bandage in the affected limb also contributed 
remarkably to the recession in lymphoedema. The 
finding also demonstrated the efficacy of a single 
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dose combination of ivermectin and albendazole in the management of this condition.
Plate 1: Wet mount micrograph showing anterior end of W. bancrofti in serum of patient (X 40 objective)
Plate 2: Wet mount micrograph showing anterior and posterior end of W. bancrofti in serum of patient (X 40 
objective)
Concerning the drug treatment of lymphatic filariasis, 
diethylcarbamazine (DEC) is effective against both 
microfilaria and adult worms. DEC lowers the blood 
microfilaria levels significantly even in single annual 
doses of 6 mg/kg which is sustained (Emilio, 2008) 
and as effective as the same dose that was earlier 
recommended daily for 12 days by WHO (Ottesen et 
al., 1997). The transmission of this disease is 
prevented by the sustained destruction of microfilaria 
from a single annual dose of DEC (Emilio, 2008). 
The adverse effects produced by the drug are due to 
their rapid destruction of microfilaria which is 
characterized by fever, headache, myalgia, sore throat 
and cough lasting for up to 24-48 hours (Andrade et 
al., 1995). These are usually mild and self-limiting 
requiring only symptomatic treatment. Ivermectin
Lowers blood microfilaria like DEC for up to one 
year by a single dose of 200 to 400ug/kg 
(Chodakewitz, 1995; Cao et al., 1997).
The adverse effects in microfilaraemic patients are 
similar to those produced by DEC but are milder due 
to the slower clearance of parasitaemia. It is the drug 
of choice for the treatment of onchocerciasis because 
of its safety and efficacy, when compared to DEC. It 
is also the drug of choice for prevention of filariasis 
in African countries endemic for Onchocerca and 
Loa loa, where DEC cannot be used due to possible 
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severe adverse reactions (Emilio, 2008). Albendazole 
destroys the adult filarial worms when given in doses 
of 400 mg twice daily for two weeks. The death of 
the adult worm induces severe scrotal reactions in 
bancroftian filariasis since this is the common site 
where they are lodged (Jayakody et al., 1993). 
Albendazole has no direct action against the 
microfilaria and does not immediately lower the 
microfilaria counts. But when given in single dose of 
400 mg in combination with DEC or ivermectin, the 
destruction of microfilaria by these drugs becomes 
more pronounced. Albendazole combined with DEC 
or ivermectin is recommended in the global filariasis 
eradication programme. This not only will prevent 
transmission of filariasis in the community by 
reducing the microfilaria levels, but also will add the 
benefit of clearing the intestinal helminths (Shenoy et 
al., 2000).
CONCLUSION
Lymphatic filariasis is a major debilitating parasitic 
infection in the tropics. Although upper limb 
involvement is uncommon in our setting, this case 
report reveals the need to embark on an 
epidemiological survey in the affected community. 
Additionally, the use of a single dose combination of 
ivermectin and albendazole is efficacious in our 
setting.
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